Migraine, reimbursement ok for preventive oral therapy in adults
(Adnkronos) – AbbVie announces reimbursement approval for atogepant for the treatment of adults experiencing at least 8 days of disabling migraine per month in the past 3 months. This approval – reports a note – makes atogepant the first oral calcitonin gene-related peptide (CGRP) receptor antagonist reimbursed for the preventive treatment of episodic and chronic … Read more